United Therapeutics Corp. ((UTHR)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
United Therapeutics Corp. is conducting a Phase 3 study titled ‘A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF).’ The study aims to assess the safety and efficacy of inhaled treprostinil in patients with progressive pulmonary fibrosis over a 52-week period, highlighting its potential to improve treatment outcomes for this condition.
The intervention being tested is inhaled treprostinil, delivered via an ultrasonic nebulizer. This drug is designed to help manage symptoms of progressive pulmonary fibrosis by improving lung function and overall patient quality of life.
This is a randomized, double-blind, placebo-controlled study with a parallel intervention model. The primary purpose is treatment, and the study employs quadruple masking to ensure unbiased results. Participants are randomly assigned to receive either the active drug or a placebo.
The study began on October 30, 2023, with primary completion expected around 2025. The last update was submitted on July 25, 2025. These dates are crucial for tracking the study’s progress and anticipating future developments.
The outcome of this study could significantly impact United Therapeutics’ stock performance, as positive results may enhance investor confidence and position the company favorably against competitors in the pulmonary fibrosis treatment market.
The study is currently ongoing, with further details available on the ClinicalTrials portal.